HomeTOP STORIESEli Lilly outlines $80B–$83B 2026 revenue target amid robust incretin growth and... Eli Lilly outlines $80B–$83B 2026 revenue target amid robust incretin growth and new product launches By rogerjudd February 5, 2026 FacebookTwitterPinterestWhatsApp Post Content Previous articleCoherent signals double-digit revenue growth for March and June quarters, eyes fiscal 2027 accelerationNext articleRegional Management targets 20%-25% net income growth and at least 10% receivables expansion in 2026 while advancing bank partnership strategy latest articles The inflation process has shifted even as headline CPI declined – Federal Reserve Cerrado Gold reports Q4 results As H-1B Visa Program Changes, Skilled Foreign Workers Consider Leaving U.S. They Get Drunk Without Drinking: What It’s Like to Have Auto-brewery Syndrome Parents Who Borrowed for Children’s College Face Looming Deadline Watch: Artemis II’s journey so far… in 85 seconds explore more The inflation process has shifted even as headline CPI declined – Federal Reserve Cerrado Gold reports Q4 results As H-1B Visa Program Changes, Skilled Foreign Workers Consider Leaving U.S. They Get Drunk Without Drinking: What It’s Like to Have Auto-brewery Syndrome Parents Who Borrowed for Children’s College Face Looming Deadline Watch: Artemis II’s journey so far… in 85 seconds
